{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:07:06Z","timestamp":1785416826011,"version":"3.56.0"},"reference-count":7,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"DOI":"10.25259\/ijdvl_68_2024","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:12:02Z","timestamp":1716163922000},"page":"501-503","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bullous pemphigoid induced by camrelizumab"],"prefix":"10.25259","volume":"92","author":[{"given":"Qin","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqian","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Nong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"10.25259\/IJDVL_68_2024\/ref-1","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.25259\/IJDVL_68_2024\/ref-2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2017.05.006","article-title":"Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis","volume":"77","author":"Atzmony","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_68_2024\/ref-3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316786","article-title":"From molecular insights to clinical perspectives in drug-associated bullous pemphigoid","volume":"24","author":"de Nicolas-Ruanes","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.25259\/IJDVL_68_2024\/ref-4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"108","author":"Quezada","year":"2013","journal-title":"Br J Cancer"},{"key":"10.25259\/IJDVL_68_2024\/ref-5","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.21037\/jtd-23-1408","article-title":"Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: A prospective multicenter observational cohort study","volume":"15","author":"Zhang","year":"2023","journal-title":"J Thorac Dis"},{"key":"10.25259\/IJDVL_68_2024\/ref-6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_68_2024\/ref-7","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jdcr.2019.07.015","article-title":"Nonbullous pemphigoid secondary to PD-1 inhibition","volume":"5","author":"Singer","year":"2019","journal-title":"JAAD Case Rep"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ijdvl.com\/bullous-pemphigoid-induced-by-camrelizumab\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ijdvl.com\/bullous-pemphigoid-induced-by-camrelizumab\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:18:15Z","timestamp":1782562695000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/bullous-pemphigoid-induced-by-camrelizumab\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":7,"alternative-id":["10.25259\/IJDVL_68_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_68_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"article-number":"501"}}